Various clinical efficacy of sodium-glucose co-transporter-2 inhibitor (SGLT2i) to sarcopenia, muscle mass and function

Regarding pharmacological therapy for diabetes, sodium-glucose co-transporter-2 inhibitor (SGLT2i) has been in focus for various clinical efficacy. They include cardiovascular disease, chronic heart failure (CHF) and chronic kidney disease (CKD). Various discussion has been observed concerning the relationship among diabetes, frailty, sarcopenia, SGLT2i, aging and senile syndrome. By SGLT2i, weight and visceral fat area (VFA) are decreased, and the results of skeletal muscle index (SMI) and bone mineral content (BMC) vary in some reports. Using abdominal CT, bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), muscle mass and BMC have been lately studied. SGLT2i may maintain muscle mass and function.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.